|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Renin-angiotensin system inhibitors (RASi) are the most effective treatments for diabetic kidney disease but significant residual renal risk remains, possibly because of other mechanisms of kidney disease progression unrelated to RAS that may be present.
|
31742881 |
2020 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The levels of the full-length form of the (pro)renin receptor (PRR), a component of the renin-angiotensin system (RAS), may be reduced in the membranes of kidneys in renal diseases.
|
30843967 |
2019 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Genetic associations between genes in the renin-angiotensin-aldosterone system and renal disease: a systematic review and meta-analysis.
|
31048445 |
2019 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The progression of kidney disease in some patients with type 2 diabetes mellitus may not be adequately suppressed by renin-angiotensin system inhibitors.
|
31248950 |
2019 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Angiotensin II and aldosterone are the main effectors of the renin-angiotensin aldosterone system (RAAS) and have a central role in hypertension as well as cardiovascular and renal disease.
|
31425690 |
2019 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Renin-angiotensin system inhibitors (RAS) drugs have a proteinuria-reducing effect that could prevent the progression of kidney disease in diabetic patients.
|
30817790 |
2019 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The role of the renin-angiotensin-aldosterone system in the pathophysiology of hypertension, and cardiovascular and kidney diseases is well known and the renin-angiotensin-aldosterone system is a major regulator of blood pressure through its effect on body fluids and electrolyte homeostasis.
|
31472818 |
2019 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Most of the patients with cognitive decline suffer of various metabolic imbalances, hypertension, cardiac and kidney disease, many of them which are treated with oral administration of Renin-angiotensin aldosterone system-altering agents like those presented above.
|
31106575 |
2019 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In the multivariate logistic regression analyses, IH-HSBP was prognostic factor for the development of nephropathy after adjusting for sex, age, duration of diabetes mellitus, body mass index, total cholesterol, hemoglobin A1c, creatinine, smoking habits and use of renin-angiotensin-aldosterone system inhibitors (odds ratio: 2.53, 95% confidence interval: 1.16-5.56, p = 0.020).
|
31711859 |
2019 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Despite optimal management of diabetic kidney disease (DKD) with intensive glycemic control and administration of agents blocking the renin-angiotensinaldosterone- system, the residual risk for nephropathy progression to end-stage-renal-disease (ESRD) remains high.
|
29792136 |
2019 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In this review, we primarily expatiate the new advances on mediators that might be amenable to targeting aging kidney and kidney diseases, including nicotinamide adenine dinucleotide phosphate oxidase (NOX), transforming growth factor-β (TGF-β), renin-angiotensin system (RAS), nuclear factor-erythroid 2 related factor 2 (Nrf2), peroxisome proliferator-activated γ receptor (PPARγ), advanced glycation endproducts (AGEs) as well as microRNAs and vitagenes.
|
31199964 |
2019 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Data suggest that morbidity and mortality reduction in people with heart failure and kidney disease requires use of a renin angiotensin system blocker, beta blocker, and mineralocorticoid receptor antagonist, as well as an SGLT 2 inhibitor.
|
31472881 |
2019 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Baseline data were used to describe patient characteristics and compare the adherence to ADA (American Diabetes Association) and KDIGO (Kidney Disease: Improving Global Outcomes) guidelines with respect to metabolic and blood pressure control, use of renin-angiotensin system-blocking agents, statins and acetylsalicylic acid between the countries.
|
30238781 |
2019 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Renin-angiotensin-aldosterone blockers have been known to have the benefits of delaying onset and progression of diabetic complications including nephropathy.
|
30864083 |
2019 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Discovery of a Novel Mutation in the REN Gene in Patient With Chronic Progressive Kidney Disease of Unknown Etiology Presenting With Acute Spontaneous Carotid Artery Dissection.
|
31371142 |
2019 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in the regulation of blood pressure and body fluid homeostasis and is a mainstay for the treatment of cardiovascular and renal diseases.
|
31129252 |
2019 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Renin-angiotensin-aldosterone system (RAAS) plays a central role in renal disease progression.
|
29882088 |
2019 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The critical role of the intrarenal renin-angiotensin system (RAS) in the development of kidney disease has been well demonstrated in animal and cell-culture experiments, but evidence from human kidney tissues is lacking.
|
30159797 |
2019 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Renin-angiotensin aldosterone system inhibitors are for a long time extensively used for the treatment of cardiovascular and renal diseases.
|
30681344 |
2019 |
|
Kidney Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These results demonstrated that progressive nephropathy in MI rats was associated with intrarenal activation of the renin-angiotensin-aldosterone system.
|
31228798 |
2019 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Early Renin-angiotensin System Blockade Improved Short-term and Longterm Renal Outcomes in Systemic Lupus Erythematosus Patients with Antiphospholipid-associated Nephropathy.
|
29449503 |
2018 |
|
Kidney Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The present study examined the role of (pro)renin receptor (PRR) in pathogenesis of albumin overload (AO)-induced nephropathy and activation of the intrarenal renin-angiotensin system (RAS) in rats.
|
29846109 |
2018 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Finally, half of the patients in all three age groups with heart failure and kidney disease received treatment with renin-angiotensin-system inhibitors; about two out of five patients received beta-blockers, while prescription rates of aldosterone inhibitors were low.
|
30187290 |
2018 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Albuminuria is an early marker of kidney disease in patients with diabetes and/or hypertension undetected or untreated albuminuria is a leading cause of chronic kidney disease and cardiovascular events, The purpose of the present survey was to assess the prevalence of albuminuria in patients with diabetes and hypertension, treated with a combinations of renin angiotensin aldosterone system inhibitors and dihydropyridine calcium channel blockers.
|
30327190 |
2018 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Kidney disease is an epidemic clinical problem causing significant morbidity and mortality, and current treatments are limited to renin-angiotensin system blockade or renal replacement therapy for the majority of affected individuals.
|
29605557 |
2018 |